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Abstract
Lung transplantation is increasing as a widely accepted surgical treatment for certain
type  of  end-stage  lung  disease.  Recent  technical  improvements  in  extracorporeal
membrane oxygenation (ECMO) have been able to expand the role of ECMO during
lung  transplantation.  The  evolution  of  oxygenators,  introduction  of  the  new-type
pump and tube, and improvement of percutaneous cannulation including dual lumen
single catheter resulted in the technical renaissance of ECMO for lung transplanta‐
tion.  Now,  beyond the  traditional  support  for  patients  with  severe  primary  graft
dysfunction,  ECMO can be established as essential  perioperative roles for patients
undergoing lung transplantation, such as preoperative lung protective support as a
bridge to transplantation,  replacement cardiopulmonary bypass during intraopera‐
tive support,  and rescue of various life-threatening situations after post-transplant.
After all, ECMO will be a fundamental, life-saving modality for patients during lung
transplantation.
Keywords: Perioperative procedures, lung transplantation, Perioperative procedures,
Ventilator-induced lung injury, Intensive care unit
1. Introduction
Recent expanded role of extracorporeal membrane oxygenation (ECMO) is switching the
paradigm of organ transplantation, especially in the lung. Traditionally, the role of ECMO in
the area of lung transplantation was focused in supporting patients with severe primary graft
dysfunction (PGD) after post-transplant; however, as the technical ECMO environments such
as new type of pump, oxygenator, catheter and tubing are improving, ECMO is now applied to
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
the  whole  process  of  lung  transplantation,  from  “bridge-to-transplant”  to  “rescue  post-
transplant” [1, 2].
The prevalence of lung transplantation has also increased over several decades especially in
the specific end-stage lung diseases, such as cystic fibrosis, interstitial lung disease, and chronic
obstructive lung disease. Contrary to successful early survival rate, the long-term survival rate
of lung transplantation has still seen modest improvement. In addition, the mortality of
patients on the waiting list is also concerning, consequently the interest in looking for alter‐
native strategies for patients with end-stage lung disease who wait lung transplantation has
risen considerably.
Mechanical ventilation has been applied to support the failing lung in peritransplant patients;
however, per se can aggravate respiratory failure and hemodynamic instability by increasing
the risk of ventilator-associated pneumonia and ventilator-induced lung injury [3]. Tradition‐
ally, mechanically ventilated pretransplant patients have been reported to have higher post-
transplant mortality rates than nonventilated patients [4].
At this point, ECMO can be considered an alternative bridging strategy in lung transplantation,
and now despite the complexity and side effects, the use of ECMO during lung transplantation
has risen by 150% in the recent last 2 years compared to the previous decades (1970–2010;
Figure 1). Besides the increase of amount, the characteristics of using ECMO are also evolving
(Table 1) [5].
Figure 1. Percentage of patients on ECMO at the time of transplant by year. Data obtained from the United Network
for Organ Sharing (UNOS) database 1987–2013. Adapted with permission from [1], © 2014 Gulack et al. Published un‐
der AME Publishing Company. DOI: 10.3978/j.issn.2072-1439.2014.06.04. Promotional and commercial use of the mate‐
rial in print, digital or mobile device format is prohibited without the permission from the publisher AME Publishing
Company.
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1970s 1980s 1990–2000 2000–2010 2010–June 2011
Patients listed for lung
transplantation on ECMO
1 1 22 104 58
Modes of ECLS used VA VA VA VV, VA, iLA™ VV, VA, iLA™,
hybrid
Pump configuration CPB Roller pump Roller pump Centrifugal Centrifigual
Oxygenator membrane Silicone
membrane
Polypropylene and
silicone
Polypropylene PMP PMP
Cannulation approach
innovation
Central Central Central Peripheral
Novalung®
Peripheral Avalon™
CPB, cardiopulmonary bypass; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation;
ILA™, interventional lung assist; PMP, polymethylpentene; VA, venoarterial; and VV, venovenous.
Table 1. Evolution of ECMO as a bridge to lung transplant by decade. Adapted with permission from [5], © 2013 Diaz-
Guzman et al. Published under Wolters Kluwer Health, Inc. DOI: 10.1097/MAT.0b013e31827461c2. Promotional and
commercial use of the material in print, digital or mobile device format is prohibited without the permission from the
publisher Wolters Kluwer Health.
2. Extracorporeal membrane oxygenation as a bridge to lung
transplantation
The first report of the use of ECMO as a bridge-to-transplant was published in the 1970s [6].
The patient was successfully transplanted and wean from ECMO, he died at 10 days of post-
transplant. Successful cases were reported in 1993 [7]; however, still controversies of using
ECMO as a bridge-to-transplant were noted at that time because of poor clinical outcomes, for
example, the estimated 1-year survival for the transplant of ECMO was only 40%. In addition,
the resources have been considerable for a successful transplant through ECMO bridge, such
as prolong intensive care and hospital stays, need of tracheostomy, substantial blood require‐
ment, and consequent neuromuscular complications that also required prolonged periods of
postoperative rehabilitation.
The lung allocation scoring (LAS) system, begun in 2005, can be attributable to increase the
use of ECMO as a bridge-to-transplant. Contrary to it patients before 2005 would receive lungs
only based on the length of time on the waiting list, both medical urgency and net benefit from
transplantation were incorporated to create a standardized scoring system. Since the adoption
of LAS system, patients receiving continuous mechanical ventilation get higher scores, more
likely to receive a transplant. Simultaneously, issues were arisen that ventilator-dependent
patient before transplantation may be too sick for transplantation, which may affect the post-
transplant outcomes. Direct or indirect risk factors could be considered in these patients: one
is the increased risk of “ventilator-induced lung injury (VILI)” or “ventilator-associated
pneumonia” during waiting period, and the other is “ICU-acquired weakness.”
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ECMO has been associated with avoidance of mechanical ventilation and it facilitates perio‐
perative rehabilitation. As far as minimizing VILI when using ECMO as a bridge-to-transplant,
ECMO may be beneficial for the patients waiting lung transplantation who have refractory
hypercapnic respiratory failure, which was followed by most patients with end-stage lung
disease combined with hypoxic respiratory failure. Extracorporeal CO2 removal (ECCO2R),
more commonly called as this concept instead of ECMO, reduces mechanical ventilation
requirements, enabling the use of low tidal volume and high PEEP at relatively lower respi‐
ratory rates. Recently, technological improvements, such as interventional lung-assisted
device pumpless venovenous ECMO (NovalungGmbH, Germany), a low-resistance oxygen‐
ator that offers good decarboxylation, and the CardioHelp venovenous ECCO2R device
(Maquet, Germany), have led to remove CO2 selectively including partial or full oxygenation
support [8].
Figure 2. (a) Patient ambulating on venovenous-ECMO, (b) Avalon Elite Double lumen catheter and catheter place‐
ment. Adapted with permission from [5], © 2013 Diaz-Guzman et al. Published under Wolters Kluwer Health. DOI:
10.1097/MAT.0b013e31827461c2. Promotional and commercial use of the material in print, digital or mobile device for‐
mat is prohibited without the permission from the publisher Wolters Kluwer Health.
Compared to the conventional mechanical ventilation strategy, patients who received “awake”
ECMO as a bridge-to-transplant can be liberated from bed and participate in a preoperative
“active” rehabilitation program, which consequently mitigated ICU-acquired weakness
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(Figure 2a). For this purpose, new-type single catheters, configured by double lumen, such as
“Avalon” (Figure 2b) or “Novatwin” cannula, can be preferable, which facilitate easier patient
mobilization to prevent decline in skeletal muscle dysfunction in postoperative period.
Although a direct causal relationship between preoperative rehabilitation enhanced by a
bridge-to-transplant using ECMO and postoperative exercise tolerance with ultimate clinical
outcomes has not been established, it is generally considered a standard of care to enlist all
patients into an active pulmonary rehabilitation program before transplantation or a “desti‐
nation therapy” like that seen with left ventricular-assisted devices in the area of heart
transplantation. There appears to be a benefit even in a common selected group of extremely
sick conditions before transplant despite the scarcity of data currently [9].
Until now, there are no randomized controlled trials showing the beneficial effect of ECMO
as bridge to lung transplant, several retrospective studies reported acceptable survival and its
feasibility. Because most of these analyses were composed of many heterogeneous patients'
feature, whether ECMO as an alternative, rather than an adjunction, to invasive mechanical
ventilation is a better bridging strategy during lung transplantation still remains an unresolved
issue. A meta-analysis of 14 retrospective studies [10–23] reported from 50 to 90% of the post-
transplant 1-year survival rate, which was significantly better in spontaneously breathing
patients or when the ECMO bridge duration was shorter than 14 days.(Tables 2 and 3) [4].
Author, year Patients,
number
Age
(years)
Sex male,
n (%)
Diagnosis Ventilation
strategy
Bridge time
(days)
Severity score
prebridge
Mason, 2010
[19] 
51 39±22 25 (49%) PF 27%; COPD 1996; CF
12%; PH 9.8%; sarcoidosis
2%; other 20%
 na na LAS 54±21
Bermudez, 2011
[11] 
17  40±14  7 (41%)  PF 35%; Re-LTx 35%; CF
23%; COPD 6% 
 MV 3.2 (0–49)  na
Hammainen,
2011 [15] 
16  41±8a 7 (58%)  PF 37%a; PH 15%a; CF 8%a;
ARDS 8%a; IP 8%a; PVOD
8%a; BOS 8%a; PGD 8%a
 na 12 (1–59)  na
Shafii, 2012
[21] 
19  44 (23–
60) 
10 (53%) IP 68%; CF 16%; PH 16%   MV 13 6±5  LAS 87 (64–
95) 
Nosotti, 2012
[20] 
11  34±13  5 (45%)  na   Awake 7
MV 4
12.1±14.7  SOFA
4.9±1.4 
Javidfar, 2012
[17] 
18  34 (22–
50) 
8 (45%)  CF 44%; PF 33%; PH 11%;
Other 11% 
 Awake 6 11.5 (6–18)  LAS 93(90–
94) 
George, 2012
[14] 
122  48±16  74 (60%) PF 29.5%; CF 11.5%; COPD
10.7%; PH 2.5%; other
45.8% 
 na na  LAS
73.9±21.4 
Fuehner, 2012
[13] 
26  44 (23–
62) 
21 (81%) PF 35%; PH 27%; CF 19%;
BOS 12%; sarcoidosis 4% 
Awake 19
MV 7
9 (1–45)  SOFA 7 (6–
12) 
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Author, year Patients,
number
Age
(years)
Sex male,
n (%)
Diagnosis Ventilation
strategy
Bridge time
(days)
Severity score
prebridge
Hoopes, 2013
[16] 
31  45±15  21 (67%) PF 29%; CF 23%; ILD 13%;
ARDS 10%;
PVOD 10%; PH 6%;
BOS 3%; IP 3%; CWP 3%
Ambulatory
18 13 VM
11 (2–53)  LAS > 50 
Anile, 2013
[10] 
12  na  na  CF 92%; histiocytosis 8%  Awake 2
MV 10
6±2.1  na 
Toyoda, 2013
[22] 
31  46±15a  10 (43%)a  Pf 33%a; CF 21%a; Re-LTx
13%a; scleroderma 13%a;
bronchiectasis 8%a; COPD
4%a; sarcoidosis 4%a; PH
4%a 
MVa  7.1±10  Las 87±9 a 
Weig, 2013
[23] 
26  36 (30–
51)a 
14 (54%) PF 62%; CF 23%; COPD 4%;
Re-LTx 4%; lung cancer 4%;
sarcoidosis 4% 
 na 16 (88–25)a  SOFA 9 (8.5–
10.5)a 
Crotti, 2013
[12] 
25  41±12  na  PF 52%; CF 16%; PH 16%;
Re-LTx 12%; ARDS 4% 
Awake 10
MV 15
5.8±4.5 versus
29.8±11.5a 
SOFA
5.6±1.9 
Lafarge, 2013
[18]
36 31 (22–48) 19 (53%) CF 56%; PF 30%; other 14% MV 3.5 (2–7) na
Data presented in this table refer to patients underwent ECMO support with the intention to bridge to lung
transplantation.
aTransplanted patients (when data for all enrolled patients are not available; Hemmainen et al., all data; Toyoda, all
data; Weig et al., ECMO bridge time and SOFA; Anile, diagnosis). ECMO bridge time (days) and the prebridge
severity score are expressed as mean± standard deviation or median and range. When no descriptive cumulative data
for the overall population are provided, they are calculated from raw data presented in the original papers.
bData refer to patients divided according to waiting time on ECMO: up to 14 days or longer.
Pts, patients; ECMO, extracorporeal membrane oxygenation; PF, pulmonary fibrosis; COPD, chronic obstructive
pulmonary disease; CF, cystic fibrosis; PH, pulmonary hypertersion; Re-LTx, Re-lung transplantation; ARDS, acute
respiratory distress syndrome; IP, interstitial pneumonia; PVOD, pulmonary veno-occlusive disease, bronchiolitis
obliterans syndrome; PGD, primary graft dysfunctions ILD, interstitial lung disease; CWP, coal workers,
pneumoconiosis; MV, mechanical vertilation; LAS, lung allocation score; SOFA, sequential organ failure assessment;
and na, not available.
Table 2. Characteristics of patients who underwent ECMO bridge to lung transplant. Reproduced from [4], © 2015
Chiumello et al. Published under CC BY 4.0 license. DOI: 10.1186/s13054-014-0686-7.
Author, year Ltx/total
patients, n
Died before Ltx, n (%) Type of
bypass
Survival at
1  year
post-LTx
(%)
Length of stay
post-LTx (days)
MV (days
post-LTx)
Mason, 2010 [19]  51/51 na na 50% 24 (9–55) H na
Bermudez, 2011
[11] 
14/17 3 (17%): neurologic
dysfunction, thrombosis 
W, VA 74% 16 (3–40) ICU) 12 (2–20)
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Author, year Ltx/total
patients, n
Died before Ltx, n (%) Type of
bypass
Survival at
1  year
post-LTx
(%)
Length of stay
post-LTx (days)
MV (days
post-LTx)
Hammainen, 2011
[15] 
13/16 3 (19%): septic MOF  W, VA 92% 22 (3–63) ICU na
Shafii, 2012 [21]  14/19 5 (26%): septic MOF 2, DC 2,
and anoxic brain injury 1 
W, VA 75% 42 (19–175) H 22 (5–125)
Nosotti, 2012 [20]  11/11 na W 87% and
50%b
47.6±21.9 H
30±20.4 ICU
27.1±20.7
Javidfar, 2012
[17] 
10/18a 8 (44%): pneumonia 1,  
MOF 6, and CA 1 
W, VA 60% 22 (18–33) H 47
(41–52) ICU
na
George, 2012 [10]  122/122 na na 57.6% 32 (16.5–60) H na
Fuehner, 2012
[13] 
20/26 6 (23%): CA 2, septic MOF
4 
W, VA 6 months
80%
38 (20–87) H 18
(1–69) ICU
14 (0–64)
Hoopes, 2013 [16] 31/31 na VA, W 93% 31 (12–86)eH na
Anile, 2013 [10]  7/12 5 (41%) W, VA 85.7% 29 (15–59) H <5
Toyoda, 2013 [22] 24/31 7(22%) W, VA 74% 46 median H na
Weig, 2013 [23]  13/26 13 (50%): acute liver failure
 7, thoracic bleeding 3,
cerebral hemorrhage 1, and
PE 2 
W, VA 54% na na
Crotti, 2013 [12]  17/25 8 (32%): MOF 3,  septic
shock 2, cardiogenic  shock
2, and intestinal ischemia 1 
W, VA 82% and
29%c
na 12.2±11.9d
Lafarge, 2013 [18] 30/36 6 (17%): GI bleeding 1,   
DIC 1, cerebral hemorrhage
1, CA 1, septic shock 1, and
therapeutic limitation 1 
W, VA,CPB 66.5% na na
Data are expressed as mean±standard deviation or median and range. Mason et al., Nosotti et al., and George et al.
enrolled transplanted patients.
aThree of the eight patients who died had transiently recovered their baseline function and were weaned from ECMO
support; they subsequently died before LTx.
bECMO group: 87% awake (7 pts); mechanical ventilation ECMO group: 50% (4 pts);
c82% patients on ECMO bridge <14 days (early); 29% patients on ECMO bridge >14 days (late);
d12.2±11.9 days (early group) −45.3±33.5 (late group).
eLTx, lung transplant; CA, cardiac arrest; MOF, multiorgan failure; DIC, disseminated intravascular coagulation; Gl,
gastrointestinal; VV, venovenous; VA, venoarterial; CPB, cardiopulmonary bypass; MV, mechanical ventilation; LOS,
length of stay; H, hospital; and na, not available.
Table 3. Summary of outcomes. Reproduced from [4], © 2015 Chiumello et al. Published under CC BY 4.0 license. DOI:
10.1186/s13054-014-0686-7.
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3. Extracorporeal membrane oxygenation during lung transplantation
There is little evidence or protocol about how to manage ECMO during intraoperative
situation; however, the intraoperative use of ECMO may be necessary at any stage of devel‐
oping hypoxia, hypercapnia, and/or hemodynamic instability. In bilateral lung transplanta‐
tion, ECMO can stabilize hemodynamic variables and prevent “first lung syndrome,” the
hyperperfusion of the first implanted lung during implantation of the second lung. In addition,
it can also be used at every phase during lung transplantation to enhance a protective venti‐
lation strategy and avoid 100% oxygen so as to mitigate the reperfusion syndrome especially
during one-lung ventilation or to support when there was a lung size mismatch, auto-PEEP,
and dynamic hyperinflation [8].
Because of many advantages mentioned earlier, ECMO has replaced CPB as the first option
for intraoperative support during lung transplantation in many transplant centers. A recent
published study from Germany showed 5-year experience with intraoperative ECMO in lung
transplantation since April 2010 [10]. Compared with patients who underwent lung trans‐
plantation without ECMO, overall survival at 1 and 4 years was not inferior in patients in
whom the indication for ECMO support and the intraoperative use of ECMO did not emerge
as a risk factor for mortality. Though small numbers were included, many studies showed
overall clinical beneficiary of ECMO over CPB during lung transplantation, such as lesser
intraoperative blood transfusion requirement, lesser mechanical ventilation requirement,
shorter ICU stay, and higher postoperative complications.
Bermudez et al. [11] compared 49 VA-ECMOs with 222 CPBs using intraoperative lung
transplantation. In this study, there was a higher requirement for reintubation, tracheostomy,
and dialysis in the CPB group; however, the lack of significant differences in perioperative
blood transfusion requirement and hospital length of stay may have been caused by the ECMO
group including a sicker population, such as the higher LAS (73.3 vs. 52.9) and higher
pretransplantation ECMO requirement (42.8% vs. 7.2%). Though most of these studies did not
show any difference in the survival curve between two groups, one study [12] revealed the
hospital mortality gain of CPB over ECMO (39% vs. 13%); however, it should be considered
that there were more planned ECMOs than CPBs (61% vs. 28%) in this study, which may not
be ignored showing the different mortality between two groups.
4. Extracorporeal membrane oxygenation as a rescue postlung transplant
In the postopertative setting of lung transplantation, early primary graft dysfunction (PGD),
which is a syndrome consisting of lung injury during the first 72 hours following lung
transplant defined as a physiologically decreased oxygenation and radiologically diffuse
infiltrates, continues to be a major situation of morbidity and mortality. There is no doubt that
ECMO has been applied as a pivotal management strategy to support severe PGD because
none of interventions to ameliorate the effects of PGD on transplanted lung have been
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successful, including inhaled nitric oxide and prostaglandins. Although about 5% of lung
transplantation requires ECMO support for PGD, this remains the most common indication
for ECMO use as a rescue strategy and consequently it is reasonable that the concept of “bridge-
to-transplant” has been arisen from the intermittent successes of a bridge to redo transplant
in selected patients [1].
The goal of ECMO for severe PGD after lung transplant, same as mentioned in bridging-to-
transplant, should be to minimize ventilator-induced lung injury such as elevated airway
pressures or high inspired oxygen concentration by mechanical ventilation with positive
pressure. While about this no uniform guidelines exist, one recommendation how to use
ECMO to support PGD after lung transplant consists of initiating it when peak inspiratory
pressure reaches up to 35 cm H2O or 60% FiO2 [13]. In addition, if possible, it could not be
delayed greater than 48 hours to initiate ECMO after transplantation because of alleged worse
outcomes. Hartwig et al. [14] reported surprising survival result in this group patients
supported with VV-ECMO. Of the recipients from VV-ECMO following transplant, 96%
weaned successfully with a 1-year survival of 64%.
Promisingly, ex vivo lung perfusion (EVLP), a novel technique used to evaluate and recondi‐
tion marginal or rejected grafts, is also adapted during lung transplantation. The retrieved
donor lung can be perfused in an ex vivo circuit, providing an opportunity to reassess its
function before transplantation for the purpose of increasing successful transplantation with
high-risk donor lungs. Cypel et al. [15] showed physiologically stable donor lung during 4
hours of ex vivo perfusion and its feasibility regarding less PGD event. Although the result
was statistically not significant, this was the first report that demonstrates the possibility of ex
vivo using ECMO for lung transplantation, remained and cited as the reference protocol.
Recently, Boffini et al. [16] also revealed that the use of initially rejected grafts treated with
EVLP did not increase severity of PGD after lung transplantation, suggesting a protective role
of EVLP against PGD.
5. Conclusions
Recently, Biscotti et al. suggested the decision algorithm of how to use ECMO during entire
lung transplantation (Figure 3) [2]. Though the details are not described in this chapter, the
interhospital transport of lung transplantation candidate during ECMO is also feasible and
this is opening a kind of new future episode [17].
Modern experience with ECMO and reported institutional experience on survival challenge
historical assumptions about the treatment of end-stage lung disease and suggest that
“bridging” to transplant with ECMO is both technically feasible and logistically viable. It is
clear at this point that continued advances in the technologies and further research will help
determine how best to include ECMO as a bridging strategy for lung transplantation.
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Figure 3. Decision algorithm of ECMO for lung transplantation. DLC, double lumen cannula; MDR, multidrug resist‐
ant; MOF, multiorgan failure; PALA, pulmonary artery to left atrium; PH, pulmonary hypertension; RIJ, right internal
jugular vein; and SCA, subclavian artery. Adapted with permission from [2], © 2015 Biscotti et al. Published under
Elsevier. DOI: http://dx.doi.org/10.1016/j.thorsurg.2014.09.010. Promotional and commercial use of the material in
print, digital or mobile device format is prohibited without the permission from the publisher Elsevier.
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